Scholar Rock Holding Corporation Common Stock, also called Scholar Rock, is a biopharmaceutical company, which engages in developing and commercializing drug products. The company focuses on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Read More Its product candidate includes SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.